Funding for this research was provided by:
Novo Nordisk Inc (N/A)
Received: 11 January 2020
Accepted: 30 August 2020
First Online: 6 October 2020
Ethics approval and consent to participate
: Approval was obtained from relevant ethics committees, and written consent was obtained from all participants or guardians/legal representatives. ANSWER was conducted in accordance with the Declaration of Helsinki, Guideline for Good Pharmacoepidemiology Practices, and regulatory requirements.
: Not applicable as all data were pseudonymized.
: BSM – Research support: Abbvie, Alexion, Amgen, Novo Nordisk, OPKO, Orphan Reach, Sandoz, Sanofi Genzyme, and Takeda; Consultancy: Ascendis, BioMarin, Bluebird Bio, GeneScience, Novo Nordisk, Pfizer, Sandoz, Sanofi Genzyme, Soleno, Takeda and Tolmar. JR – Research support: Novo Nordisk; Consultancy: Novo Nordisk; Data Safety Monitoring Board: OPKO. VO – Employee of Novo Nordisk.